LuciUpa
Original price was: $400.00.$233.84Current price is: $233.84.
Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
In Stock
Description
COMPOSITION:
Each film-coated tablet contains Upadacitinib… 15 mg.
INDICATION:
LuciUpa is a Janus kinase (JAK) inhibitor indicated for the treatment of:
• Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
• Adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers.
• Adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers.
DOSAGE AND USE:
• Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Non-radiographic Axial Spondyloarthritis the recommended dosage is 15 mg once daily.
• Ulcerative Colitis the recommended induction dosage is 45 mg once daily for 8 weeks. The recommended maintenance dosage is 15 mg once daily.
STORAGE:
in a dry place and store at 20°C to 25°C.
MANUFACTURED AND MARKETED BY:
LUCIUS PHARMACEUTICALS(LAO) CO., LTD
No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING:
Keep medicine out of reach of Children. Do not administer LuciUpa during Pregnancy and Lactation.
Reviews
There are no reviews yet.